The pending patent relates to system-level technology relevant to advanced glucose management solutions. Final grant of this European Patent Application No. 22740529.7 (“Artificial Pancreas 2021”) is expected following completion of formal grant formalities within a prescribed period.

The intended grant of the patent application strengthens Lifecare’s protection at the system and control level, complementing its chemistry and sensor architecture portfolio.

Structured and evolving IP strategy

Lifecare operates a structured and dynamic intellectual property strategy aligned with its long-term platform ambitions.

The Company’s IP foundation is built on four complementary pillars:

1. Core proprietary patents covering osmotic pressure-based sensing principles and sensor architecture.
2. Ongoing patent applications reflecting continued R&D progress.
3. Strategic collaboration-based rights and licensed technologies.
4. Proprietary know-how and system integration expertise protected through confidentiality and operational control.

This integrated approach reflects Lifecare’s position as a platform technology company, where competitive advantage arises from the interaction between chemistry, sensing physics, electronics, manufacturing processes and system integration.

Core granted patents

Lifecare holds several granted patents central to its implantable osmotic sensing technology, including:

• Apparatus and Method for Measuring Augmented Osmotic Pressure in a Reference Cavity (granted 2018; expiry 2030) – core osmotic pressure measurement principle.
• Interstitial Fluid Osmotic Pressure Measuring Device System and Method (granted 2011; expiry 2038) – foundational sensor architecture.
• Fluid composition, method for preparing the composition and use (granted 2024; expiry 2038) – active fluid chemistry used in sensor applications.

These patents form the backbone of Lifecare’s current implantable CGM development program.

Chemistry development beyond glucose

Lifecare currently has two pending patent applications related to chemistry compositions, of which one is related specifically to modular compositions. These filings support the Company’s long-term ambition to extend its osmotic sensing platform beyond glucose monitoring toward broader biomarker detection.

As part of normal portfolio management in research-driven technology companies, patent applications are continuously refined to reflect ongoing R&D progress and technical maturation. The current filing builds on advancements achieved following the initial May 2024 filing and reflects an expanded and improved technical scope aligned with Lifecare’s broader platform ambitions.

This iterative development process is aligned with Lifecare’s strategy of strengthening its platform protection as technical insights evolve.

Expansion of sensing technologies

In parallel with chemistry development, Lifecare has expanded its technology optionality on the sensing side.

Through its collaboration framework with Johann Wolfgang Goethe-Universität Frankfurt am Main (GUF), established in 2022, Lifecare holds defined R&D rights and an option pathway to commercial rights related to Surface Acoustic Wave (SAW) sensor technology.

While Lifecare’s first-generation product utilizes commercially available piezoresistive pressure sensors, both SAW and Nano Tunneling Resistor (NTR) technologies represent future miniaturisation and sensitivity pathways.

Together, these initiatives reflect a deliberate strategy to expand the Company’s platform in two dimensions:

• Broader chemistry capable of detecting additional biomarkers.
• Multiple sensing mechanisms capable of translating biochemical changes into measurable signals.

Lifecare considers its patent portfolio, collaborative rights, and proprietary know-how to be aligned with the Company’s current development stage and long-term commercial strategy.